A phase II study of bortezomib in patients with MALT lymphoma

被引：56
作者：
Troch, Marlene [1 ]
Jonak, Constanze [1 ]
Muellauer, Leonhard [2 ]
Puespoek, Andreas [3 ]
Formanek, Michael
Hauff, Wolfgang
Zielinski, Christoph C. [1 ]
Chott, Andreas [2 ]
Raderer, Markus [1 ]
机构：
[1] Med Univ Vienna, Div Oncol, Dept Internal Med 1, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 3, A-1090 Vienna, Austria
[3] Med Univ Vienna, Div Gastroenterol, A-1090 Vienna, Austria
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 05期
关键词：
bortezomib; MALT lymphoma; chemotherapy; B-CELL LYMPHOMA; HELICOBACTER-PYLORI; TISSUE LYMPHOMA; MARGINAL ZONE; ERADICATION; EXPERIENCE; CHLORAMBUCIL; PREDNISONE; SERIES;
D O I：
10.3324/haematol.2008.001537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We have performed a phase II study to evaluate bortezomib in patients with MALT-lymphoma. Sixteen patients entered the trial, 4 had gastric MALT-lymphoma, 7 of the ocular adnexa, one of the colon, and 2 of the parotid, and one patient each the lung and the breast. Bortezomib was given at 1.5 mg/m(2) days 1, 4, 8 and 11; repeated every 21 days. The overall response rate was 80% (13/16); 7 patients achieved complete remission (43%), 6 partial response (37%) and 3 stable disease. After a median follow-up of 23 months (range 8-26); all patients are alive and 4 have relapsed. Fifteen patients required dose reductions due to either neuropathy (7 patients) or diarrhea (8 patients). Bortezomib appears to be active in patients with MALT-lymphoma. However, an unexpectedly high rate of toxicities was seen, warranting assessment of combination schedules with bortezomib at a lower dose than given in our study (ClinicalTrials.govIdentifier: NCT 003073906).
引用
收藏
页码：738 / 742
页数：5
相关论文
共 22 条
  • [1] Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach -: Results of a controlled clinical trial
    Avilés, A
    Nambo, MJ
    Neri, N
    Talavera, A
    Cleto, S
    [J]. MEDICAL ONCOLOGY, 2005, 22 (01) : 57 - 62
  • [2] Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit
    Ben Simon, Guy J.
    Cheung, Ning
    McKelvie, Penny
    Fox, Richard
    McNab, Alan A.
    [J]. OPHTHALMOLOGY, 2006, 113 (07) : 1209 - 1213
  • [3] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [4] Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma
    Copie-Bergman, C
    Gaulard, P
    Lavergne-Slove, A
    Brousse, N
    Fléjou, JF
    Dordonne, K
    de Mascarel, A
    Wotherspoon, AC
    [J]. GUT, 2003, 52 (11) : 1656 - 1656
  • [5] Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy:: experience from a large international series
    Fischbach, W.
    Goebeler, M. E.
    Ruskone-Fourmestraux, A.
    Wuendisch, T.
    Neubauer, A.
    Raderer, M.
    Savio, A.
    [J]. GUT, 2007, 56 (12) : 1685 - 1687
  • [6] Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy:: experience from a large prospective series
    Fischbach, W
    Goebeler-Kolve, ME
    Dragosics, B
    Greiner, A
    Stolte, M
    [J]. GUT, 2004, 53 (01) : 34 - 37
  • [7] Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, JE
    Hagemeister, F
    Fayad, L
    Dang, NH
    Samaniego, F
    Wang, M
    Broglio, K
    Samuels, B
    Gilles, F
    Sarris, AH
    Hart, S
    Trehu, E
    Schenkein, D
    Cabanillas, F
    Rodriguez, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 667 - 675
  • [8] Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    Hideshima, T
    Mitsiades, C
    Akiyama, M
    Hayashi, T
    Chauhan, D
    Richardson, P
    Schlossman, R
    Podar, K
    Munshi, NC
    Mitsiades, N
    Anderson, KC
    [J]. BLOOD, 2003, 101 (04) : 1530 - 1534
  • [9] Isaacson P.G., 2001, WHO CLASSIFICATION T, P157
  • [10] Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine:: 6 year follow-up of a phase II trial
    Jaeger, G.
    Neumeister, P.
    Quehenberger, F.
    Woehrer, S.
    Linkesch, W.
    Raderer, M.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (11)
123